000 01817nam  2200349zi 4500
0019.935755
003CaOODSP
00520240607132851
006m     o  d f      
007cr mn|||||||||
008240321e20240517onc     ob   f000 0 eng d
020 |a9780660709413
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aHP40-355/3-2024E-PDF
24500|aStatement on the prevention of respiratory syncytial virus (RSV) disease in infants : |bsupplementary systematic review of economic evidence.
264 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cMay 17, 2024.
264 4|c©2024
300 |a1 online resource (18 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aCover title.
500 |aIssued also in French under title: Déclaration sur la prévention de la maladie causée par le virus respiratoire syncytial (VRS) chez les nourrissons : examen systématique supplémentaire des évaluations économiques.
500 |aAt head of title: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).
500 |aIncorrect catalogue number (HP40-355/2-2024E-PDF) printed in this publication.
504 |aIncludes bibliographical references.
650 0|aRespiratory syncytial virus|zCanada|xPrevention.
650 0|aImmunization of infants|xEconomic aspects|zCanada.
7102 |aPublic Health Agency of Canada, |eissuing body.
77508|tDéclaration sur la prévention de la maladie causée par le virus respiratoire syncytial (VRS) chez les nourrissons : |w(CaOODSP)9.935756
85640|qPDF|s461 KB|uhttps://publications.gc.ca/collections/collection_2024/aspc-phac/HP40-355-3-2024-eng.pdf